Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FPR3 | P25089 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11960430 | 0.94 | SMN1; SMN2 (0.37) | SIGMAR1SMN1; SMN2MEN1CYP1A2KMT2A | |
| SCHEMBL11960437 | 0.87 | SIGMAR1 (0.43) | SIGMAR1SMN1; SMN2MEN1CYP1A2KMT2A | |
| SCHEMBL20124153 | 0.82 | SIGMAR1 (0.39) | SIGMAR1SMN1; SMN2MEN1CYP1A2KMT2A | |
| SCHEMBL16687691 | 0.82 | SIGMAR1 (0.39) | SIGMAR1SMN1; SMN2MEN1CYP1A2KMT2A | |
| SCHEMBL11960425 | 0.81 | SMN1; SMN2 (0.45) | SIGMAR1SMN1; SMN2CYP1A2FPR3 | |
| SCHEMBL11981726 | 0.80 | SIGMAR1 (0.40) | SIGMAR1SMN1; SMN2MEN1CYP1A2KMT2A | |
| SCHEMBL11048 | 0.76 | USP2 (0.39) | MEN1KMT2A | |
| SCHEMBL12062271 | 0.75 | GNAI3 (0.36) | SIGMAR1SMN1; SMN2CYP1A2BCHEGNAI3 | |
| SCHEMBL20124090 | 0.74 | SIGMAR1 (0.46) | SIGMAR1FPR3BCHEGNAI3GNAO1 | |
| SCHEMBL11050 | 0.74 | SIGMAR1 (0.46) | SIGMAR1FPR3BCHEGNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259825-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170320892-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | SILICON VALLEY BANK | 2017-11-09 | — | — | US | disclosed |
| US-20170320892-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | SILICON VALLEY BANK | 2017-11-09 | — | — | US | disclosed |
| US-9573962-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573962-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150274752-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2015-10-01 | — | — | US | disclosed |
| US-9023843-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120202792-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011047320-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274752-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | LPO, MPO, CAT | SIGMAR1 3393/4885SMN1; SMN2 3970/4885MEN1 3022/4885 |
| US-10259825-B2 | Antimicrobial compounds and methods of making and using the same | LPO, MPO, CAT | SIGMAR1 3393/4885SMN1; SMN2 3970/4885MEN1 3022/4885 |
| US-20120202792-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | LPO, MPO, CAT | SIGMAR1 3393/4885SMN1; SMN2 3970/4885MEN1 3022/4885 |
| US-20170320892-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | LPO, MPO, CAT | SIGMAR1 3393/4885SMN1; SMN2 3970/4885MEN1 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.